Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $453.84 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $280.06 | 2 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $73.20 | 1 | $0 (2024) |
| PFIZER INC. | $53.04 | 3 | $0 (2023) |
| Telix Pharmaceuticals | $17.56 | 1 | $0 (2023) |
| Siemens Medical Solutions USA, Inc. | $15.00 | 1 | $0 (2018) |
| ABBVIE INC. | $14.98 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $183.41 | 2 | Abbott Laboratories ($110.21) |
| 2023 | $55.60 | 3 | PFIZER INC. ($38.04) |
| 2022 | $199.83 | 3 | Abbott Laboratories ($169.85) |
| 2018 | $15.00 | 1 | Siemens Medical Solutions USA, Inc. ($15.00) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Abbott Laboratories | ABSOLUTE PRO (Device) | Food and Beverage | In-kind items and services | $110.21 | General |
| Category: Vascular | ||||||
| 09/06/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $73.20 | General |
| Category: Genetic Disease | ||||||
| 11/30/2023 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 09/13/2023 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/05/2023 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/03/2022 | Abbott Laboratories | DRAGONFLY OPSTAR (Device) | Food and Beverage | In-kind items and services | $169.85 | General |
| Category: Vascular | ||||||
| 06/28/2022 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/18/2022 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: GLAUCOMA | ||||||
| 04/23/2018 | Siemens Medical Solutions USA, Inc. | Multix Fusion (Device), SOMATOM GO, Juniper | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: DI - X-Ray Products | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 853 | 912 | $471,179 | $85,647 |
| 2022 | 9 | 681 | 846 | $561,659 | $108,800 |
| 2021 | 9 | 874 | 1,064 | $641,488 | $145,548 |
| 2020 | 9 | 685 | 969 | $460,568 | $108,527 |
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 123 | 123 | $234,200 | $46,769 | 20.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 177 | 178 | $42,441 | $11,112 | 26.2% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 64 | 64 | $76,800 | $8,044 | 10.5% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 59 | 60 | $23,600 | $5,370 | 22.8% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 62 | 62 | $25,400 | $3,105 | 12.2% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 16 | 64 | $32,000 | $2,684 | 8.4% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2023 | 23 | 27 | $13,405 | $2,576 | 19.2% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Facility | 2023 | 40 | 42 | $5,721 | $1,421 | 24.8% |
| 78582 | Nuclear medicine study of lung ventilation and circulation | Facility | 2023 | 26 | 26 | $3,565 | $1,085 | 30.4% |
| 78708 | Nuclear medicine study of kidney, blood, flow, and function with drug administration | Facility | 2023 | 20 | 22 | $3,698 | $1,071 | 29.0% |
| 78226 | Nuclear medicine study of liver and bile duct system | Facility | 2023 | 29 | 30 | $2,996 | $880.44 | 29.4% |
| J0280 | Injection, aminophyllin, up to 250 mg | Office | 2023 | 75 | 75 | $1,955 | $513.75 | 26.3% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Facility | 2023 | 48 | 48 | $1,550 | $495.84 | 32.0% |
| 78580 | Nuclear medicine study of lung circulation | Facility | 2023 | 15 | 15 | $1,828 | $425.04 | 23.3% |
| J1245 | Injection, dipyridamole, per 10 mg | Office | 2023 | 24 | 24 | $720.00 | $68.30 | 9.5% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 52 | 52 | $1,300 | $26.34 | 2.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 176 | 176 | $340,000 | $73,295 | 21.6% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2022 | 116 | 122 | $102,400 | $16,359 | 16.0% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2022 | 60 | 60 | $24,000 | $5,477 | 22.8% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 26 | 104 | $52,000 | $5,020 | 9.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 63 | 63 | $25,800 | $3,332 | 12.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2022 | 40 | 41 | $7,339 | $2,701 | 36.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2022 | 12 | 14 | $3,990 | $1,207 | 30.2% |
| J0280 | Injection, aminophyllin, up to 250 mg | Office | 2022 | 104 | 104 | $2,820 | $715.88 | 25.4% |
| J1245 | Injection, dipyridamole, per 10 mg | Office | 2022 | 54 | 132 | $2,560 | $378.21 | 14.8% |
About Dr. Sang Lee, M.D
Dr. Sang Lee, M.D is a Nuclear Imaging & Therapy healthcare provider based in Newark, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467552257.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sang Lee, M.D has received a total of $453.84 in payments from pharmaceutical and medical device companies, with $183.41 received in 2024. These payments were reported across 9 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($453.84).
As a Medicare-enrolled provider, Lee has provided services to 3,093 Medicare beneficiaries, totaling 3,791 services with total Medicare billing of $448,521. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Practice Information
- Specialty Nuclear Imaging & Therapy
- Location Newark, NJ
- Active Since 09/22/2006
- Last Updated 04/26/2016
- Taxonomy Code 207UN0902X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1467552257
Products in Payments
- DRAGONFLY OPSTAR (Device) $169.85
- ABSOLUTE PRO (Device) $110.21
- AMVUTTRA (Drug) $73.20
- VYNDAQEL (Drug) $53.04
- ILLUCCIX (Drug) $17.56
- Multix Fusion (Device) $15.00
- DURYSTA (Drug) $14.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.